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Amplified refractory mutation system 
Relapsing-remitting multiple sclerosis 
A B S T R A C T   
Multiple sclerosis (MS) is a type of autoimmune disease where immune cell attacks our cells mistakenly; its 
severity is measured by expanded disease status scale (EDSS). The study aims the investigation of − 1082 
polymorphism in interleukin 10 (IL-10) as one of the etiologies that develops the disease. This is a case-control 
study that allele-specific polymerase chain reaction (AS-PCR) were provided to compare 100 relapsing-remitting 
MS (RRMS) patients, which fulfills McDonald criteria with 100 healthy controls depending on the − 1082 (G/A) 
polymorphism of the gene encoding IL-10. The A allele frequency of IL-10 gene has been considerably less in MS 
patients compare to healthy control (60.50 Vs. 81%). Genotype distributions of the single nucleotide poly-
morphism (SNP) -1082 fulfills Hardy-Weinberg equilibrium in cases (P = 0.155) but it doesn’t in controls (P <
0.0001). In MS patients, Heterozygous (GA) genotypes were non-significantly associated with MS (OR =
0.834,95% CI = 0.6890 to 1.29, P 0.706) but homozygous (AA) were significantly associated with this condition 
(OR = 3.420, 95% CI = 1.450 to 8.065, P = 0.0037). To conclude, the genotype distribution of − 1082 (G/A) 
polymorphism has been showed a significant difference in the case/control study recruited in Erbil province-Iraq, 
and EDSS is significantly higher in A allele’s carrier genotypes. There was non-significance association AA ge-
notypes and duration of the disease.   
1. Introduction 
The most common neurological disease also regarded as an auto-
immune disease in which the insulating layer on the axon of neurons 
have degenerated and the axons are damaged is multiple sclerosis (MS) 
(Özenci et al., 2000; Huang et al., 2015). Above two million people were 
diagnosed with Multiple sclerosis MS worldwide, between the ages of 
20–40. MS includes the most prevalent symptoms which are Cognitive 
changes, fatigue, spasticity, paresis, dizziness, and tingling (Goldenberg, 
2012). The disease severity of MS is measured by EDSS. The etiology of 
this disease still is unknown, but scientists suppose both genetic and the 
environmental factors play a part in the disease pathogenesis (Gourraud 
et al., 2012). Disruption between pro-inflammatory and anti- 
inflammatory cytokine balance has been thought of as a cause for 
Abbreviation: IL-10, interleukin 10; MS, multiple sclerosis; EDSS, expanded disease status scale; GWAS, genome-wide association study; AS-PCR, allele-specific 
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increasing the probability to have this disease (Navikas and Link, 1996). 
The international MS Genetics Consortium (IMSGC) and genome-wide 
association study (GWAS) has identified hundreds of risk loci for MS 
such as tumor necrosis factor-alpha (TNF-α), human leukocyte antigen, 
IL-7, IL-2 (Arabi et al., 2018), TNF-RSF14, CD58, CD86, TNF-RSF14, IL- 
12RB1, IL-22RA2, and IL-10 (International Multiple Sclerosis Genetics 
Consortium, 2011). 
Among those interleukins, IL-10 as an immune regulator cytokine 
has a great role in maintaining the balance and the magnitude of the 
immune system and it is decrease regarded as one of the causes that 
involved in MS and its pathology (Gourraud et al., 2012). The Locus of 
IL-10 is at chromosome 1q32.1, in which it consists of 5 exons producing 
178 amino acids made IL-10 (Moore et al., 2001). As a function, it has a 
role in preventing the expression of both (T-helper 1 (Th1) cytokines and 
class II antigens of MHC, also it has a role in lowering the generation of 
many immune-active agents like TNF- α, IL-12, and metabolites of 
reactive nitric oxides. IL-10 might also boost the proliferation, survival 
and antibody production of B-lymphocyte (Moore et al., 2001). 
Multiple sclerosis (MS) patients showed a decrease in the amount of 
IL-10 mRNA expression (Van Boxel-Dezaire et al., 1999), this is linked to 
the polymorphisms that may be present in the promoter region which 
results in the production of cytokine (Weiner, 2009). Therefore SNPs 
have a crucial function which may affect the vulnerability to MS (Smith 
and Humphries, 2009). 
In the IL-10 promoter, three SNPs − 592 (A/C), − 819 (T/C) and −
1082 (G/A) are clustered that forms three haplotypes ACC, ATA, and 
GCC respectively, which they are linked to the expression rate of IL-10 
gene (Wergeland et al., 2005). In general, the haplotype containing 
− 1082*G-allele, specifically GCC/GCC, is known to be correlated with 
high IL-10 expression; while GCC/ACC and GCC/ATA have a moderate 
expression relationship, finally, ACC/ACC, ATA/ACC, and ATA/ATA are 
associated with low expression (Mihailova et al., 2005). A single study 
that had been done previously showed high IL-10 expression and cyto-
kine production in those people that carry − 1082G allele (Miteva and 
Stanilova, 2008). Even as, several researchers have investigated the 
relationship of − 1082 G/A SNP with vulnerability to MS (Azarpira et al., 
2010; Galehdari et al., 2015). Thus, our aim in this research is the study 
of the relationship of − 1082 G/A SNP in IL-10 and MS susceptibility 
within another ethnic group in Kurdish population in Iraq. This study 
aimed to investigate the relationship between IL-10 gene polymorphism 
at − 1082 (G/A) and MS susceptibility within another ethnic group in 
Kurdish population in Iraq. 
2. Materials and methods 
2.1. Sample collection and DNA analysis 
An overall five ml of peripheral blood samples in EDTA tube of 100 
MS patients (50 males and 50 females) collected from the department of 
neurology, Rzgari hospital in Erbil city, Iraq, who diagnosed according 
to the 2005 revision of McDonald criteria (Polman et al., 2005). The 
blood was also collected form 100 healthy controls (50 males and 50 
females). The MS patients who were recruited with mean age of 34.85 ±
1.442 years and of the control group was 32.25 ± 1.375 years. Statis-
tically, the ages showed non-significant difference and also the EDSS 
was measured for the patients with the mean of (3.250 ± 0.353). 
Human blood samples were taken from peripheral veins using the 
five-milliliter syringe. The blood put into K2EDTA (5.4 mg) tube for 
direct DNA extraction. The DNA was extracted using a spin column 
method (AccPrep Genomic extraction Kit- Bioneer, South Korea), 
depending on the manufacturer’s instructions. Then the concentration 
and purity of genomic DNA extracted from each human blood samples 
were determined using Nano-Drop ™ (Thermo Scientific, USA) spec-
trophotometer by recording the concentration ranged (11.05–61.60 ng/ 
μl) and purity (1.69–2.27) for each sample. MS patients and healthy 
control group with their Demographic profiles are shown in Table 1. 
Genotyping of the SNP in promoter region at position − 1082G > A of 
IL-10 gene performed by a rapid and cost-effective technique called AS- 
PCR method. In this technique we did allele-specific amplification for all 
subjects by two reactions with three DNA primers. One of the reactions is 
used to amplify the wild type allele: the primers were 5′ - CAG TGC CAA 
CTG AGA ATT TGG -3′ (common Forward primer) and 5′- CTA CTA AGG 
CTT CTT TGG GAG-3′ (reverse primer specific (G) (https://www.ncbi. 
nlm.nih.gov/tools/primer-blast/)). The other reaction used for ampli-
fication of the mutant allele: 5′ –CAG TGC CAA CTG AGA ATT TGG -3′
(common Forward primer) and 5′ – ACT ACT AAG GCT TCT TTG GGA A 
-3′ (reverse primer specific (A)) (Perrey et al., 1999). 
The total of 20 μl volume of PCR master mix reaction achieved 
containing 2 μl of genomic DNA, 10 μl Taq DNA Polymerase 2× Master 
Mix RED (Ampliqon, Danish) and 1 μl for each forward and reverse 
primers. Then 6 μl of nuclease-free water is added to complete the 
mixture. The PCR program started with initial denaturation step which 
was set at 94 ◦C for 5 min and after that the next 35 cycles 94 ◦C for 30 s 
(denaturation), 62 ◦C for 30 s (annealing), 72 ◦C for 30 s (elongation). 
The final step (extension step) was set at 72 ◦C for 5 min to extend all 
PCR fragments. After PCR amplification, the PCR DNA amplicons 
separated on 2.0% agarose gel then the separated bands were stained 
with ethidium bromide to visualize under UV light (Bio-Rad UV-trans- 
illuminator) (Brown, 2016). The 258 bp mean the appearance of IL-10 
gene polymorphism in both G and A alleles. If 258 bp was found in 
separated reactions of a sample, it was heterozygote (AG). If 258 bp was 
only seen in A allele reactions of a sample, it was mutant homozygote 
(AA), If 258 bp was only seen in G allele reactions of a sample, it was 
wild homozygote (GG). 
2.2. Statistical analysis 
Graph Pad Prism 6 and SPSS statistical softwares used for doing 
statistical analysis. All data fulfilled the criteria of performing tests of 
normality (Kolmogorov-Smirnov, Shapiro-Wilk and D’Agostino), so 
parametric tests were applied. To compare MS patients with healthy 
control group in the aspect of demographic characteristic parameters, 
the Independent t-test was used. The Chi-square (χ2) test was used to 
analyze and compare the two variables which are IL-10 genotype and 
allele frequency in both MS patients and healthy controls. We calculate 
both odds ratio (OR) and 95% confidence interval (CI) for both genotype 
and allele to estimate the correlation of the polymorphism in IL-10 
promoter region specifically the SNP -1082 (G > A) with MS. Binary 
logistic regression used to define the correlation of genotype with both 
EDSS and duration of the disease. 
The t-test and one-way ANOVA were used to know the difference 
between IL-10 gene polymorphisms and EDSS score in alleles and ge-
notypes. A statistically significant p-value of less than 5% (p < 0.05) was 
determined. 
3. Results 
All subjects were genotyped in both groups 100 RRMS patients and 
100 healthy volunteers for SNP –1082 G/A in the IL-10 gene successfully 
and approximately 10% of randomly selected DNA samples were re- 
analyzed without finding any discrepancies. In control group, the 
noticed genotypes distribution was not harmony but in patients are 
Table 1 
Demographic parameters of both MS patients and healthy control participants.  
Variable MS patients 
Mean ± SE 
Controls 
Mean ± SE 
p-Value 
MS patients 34.85 ± 1.442 32.25 ± 1.375 0.196 
EDSS 3.250 ± 0.354   
Duration of disease 4.227 ± 0.503   
Number of attacks 3.400 ± 0.395    
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harmony with Hardy–Weinberg equilibrium (P < 0.0001, p = 0.155 
respectively, χ2 test). The genotype distribution in the study population 
of RRMS cases and controls were different (GA Vs. GG, P = 0.707; AA Vs. 
GG, P = 0.004), reaching the statistical significance in AA-genotype but 
they don’t in GA-genotype. Also, a tendency for the difference of A-allele 
was observed among cases compared to controls (A Vs. G; P < 0.0001). 
Consequently, the AA genotypes increase susceptibility to the disease by 
3.420 folds. The carrying of GA-genotype was not but AA-genotype was 
associated significantly with higher risk of susceptibility to diseases (OR 
= 0.834, 95% CI = 0.6890 to 1.29, P 0.706) and (OR = 3.420, 95% CI =
1.450 to 8.065, P = 0.004) respectively. The A-alleles could be accepted 
as risk factors for RRMS (OR = 2.783, 95% CI = 1.769 to 4.379, P <
0.0001). Regarding haplotypes, we found significant association in 
dominant model comparison (GA/AA Vs. GG: OR = 3.857, 95% CI: 
2.133 to 6.974; P ≤ 0.0001), but a non-significant association was found 
in the recessive model (GG/GA Vs. GG: OR = 2.111, 95% CI: 0.927 to 
4.806; P = 0.071) (Tables 2 & 3). 
3.1. EDSS comparisons and associations in different genotypes and alleles 
Expanded disability status scale (EDSS) the number assigned to MS 
patients depending on the severity of the disease ranged from 0 to 10. 
Comparison by one-way ANOVA revealed that there are significant 
differences between genotypes (GG, GA, and AA) (p-value <0.0001). In 
Dunnett’s multiple comparisons tests showed that the mean of EDSS 
score by GA genotypes was significantly higher if compared to GG ge-
notypes (GA VS GG: 3.194 + 0.250 VS 1.286 + 0.368), similarly, the 
mean of EDSS score by AA genotypes was also significantly higher if 
compared to GG genotypes (AA VS GG: 5.833 + 0.188 VS 1.286 + 0.368) 
(Fig. 1b). Regarding the difference of EDSS in G and A alleles, the mean 
of EDSS in patients with A alleles recorded more (3.685 ± 0.264) if 
compared to G alleles (2.204 ± 0.246), their differences are significant 
(p-value <0.0001) (Fig. 1a). 
Binary logistic regression revealed that the AA genotypes associated 
with the severity of disease score (EDSS) significantly (OR = 1.087, 95% 
CI = 0.771 to 1.532, P = 0.001), but there was non-significant associ-
ation with the duration of the disease (OR = 2.671, 95% CI = 1.461 to 
4.885, P = 0.634) (Table 4). 
4. Discussion 
Multiple sclerosis is defined as a neurodegenerative disease (Bier-
nacka-Lukanty et al., 2015), that is characterized by balance interrup-
tion between pro-inflammatory (TNF alpha and IL-1) and anti- 
inflammatory cytokines (IL-4, IL6, and IL-10) (Özenci et al., 2000; Sla-
vin et al., 2010; Smail et al., 2020). Among cytokines, the Interleukin-10 
is the best-studied and most prominent in human anti-inflammatory 
cytokine, and it is the crucial target candidate-gene for genetic associ-
ation studies of developing MS susceptibility implicates (Wong et al., 
2011; Tizaoui, 2018). 
The proximal promoter region in the IL-10 gene is characterized by 
highly polymorphic due to having many SNP sites, including (− 1082A/ 
G, − 819 T/C and -592A/c) are related to the IL-10 expression, and the 
risk of MS susceptibility is connected with SNPs in IL-10 promoter region 
(Wergeland et al., 2005; Jiang et al., 2015). 
In the present study (genetic case-control studies), association of 
− 1082 G/A SNPs of IL-10 genes with MS in Erbil province Kurdistan 
Region-Iraq investigated by comparing the frequency of alleles or ge-
notypes between the cases and controls. The Genotypes expressed as AA 
(A) and GG (G) in the homozygote alleles while AG in the heterozygous 
allele. In the IL-10 − 1082 G/A SNPs position, these genetic models 
compared A/A genotypes to G/A + G/G genotypes in dominant model 
and also in the recessive model compared A/A + G/A to G/G genotypes. 
According to the result of the present study, − 1082 G/A poly-
morphism represents a statistically significant association observed be-
tween the polymorphism of IL-10 gene and susceptibility to MS. 
Furthermore, the polymorphic AG genotypes of IL-10 SNP were eluci-
dated to be non-significantly but AA-genotype frequencies increased in 
MS patients. Meanwhile, the frequencies of A were also found to be a risk 
factor to MS. 
Our results agree with previous reports which recommended that 
RRMS with GA and AA genotypes are at high risk to develop MS and the 
A allele accepted as risk factors for MS in the Kurdish population. The 
conflicting results from different communities reported. Nearly all 
studies on SNPs of IL-10 gene represented non-significant association 
with MS. Our observation contradicted the studies done by Izad et al. in 
Iranian community and Mirowska-Guzel et al. in a Polish community, 
which had not shown differences of IL-10 promoter region − 1082 G/A 
SNPs haplotypes and genotypes frequency between MS patients and 
control group (Mirowska-Guzel et al., 2011; Izad et al., 2010). Addi-
tionally, Luomala et al. exhibited that − 1082 SNP represented non- 
significant association with MS pathogenesis (Luomala et al., 2003). In 
contrast to us, both Pickard et al. and Myhr et al. studies declared that 
there were no confirmed correlation between polymorphism in IL-10 
gene promoter and disability in MS cases (Pickard et al., 1999; Myhr 
et al., 2002). On the other hand, the genetic meta-analysis also showed 
and realized statistically none-significant association between − 1082 G/ 
A SNPs of IL-10 genes and MS (Nikolopoulos et al., 2011; Ramakrishnan 
et al., 2017; Tizaoui, 2018). 
Whereas the similar results with association were obtained such as 
the studies in Europeans were done by Galehdari et al. which explained 
that the result showed a significant relationship of IL-10 promoter gene 
Table 2 
Association of MS with carriage of alleles/genotypes of IL-10.  
Polymorphism MS (N = 100) Control (N = 100) OR 95% CI P value 
No % No % 
GG 19 19 10 10 – – – 
GA 41 41 18 18 0.8341 0.689 to 1.290 0.707 
AA 40 40 72 72 3.420 1.450 to 8.065 0.004 
GA + AA 81 81 90 90 2.111 0.927 to 4.806 0.071 
GG + GA 60 60 28 28 3.857 2.133 to 6.974 <0.0001 
G 79 39.50 38 19.00 2.783 1.769 to 4.379 <0.0001 
A 121 60.50 162 81.00 
HWE 
P-Value 
0.155 <0.0001     
Table 3 
EDSS comparisons in different genotypes and alleles.  
Polymorphism MS P=Value 
EDSS 
Mean 
GG 1.286 + 0.368  <0.0001 
GA 3.194 + 0.250 
AA 5.833 + 0.188 
G 2.204 ± 0.246  <0.0001 
A 3.685 ± 0.264  
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− 1082 G/A polymorphism and the risk of MS (Nikolopoulos et al., 2011; 
Galehdari et al., 2015). Besides, Shahbazi et al. revealed the role of IL-10 
polymorphisms in the development of MS (Shahbazi et al., 2017). The 
AA genotypes are predominant in RRMS patients since this genotype 
take the responsibility of lowering the IL-10 synthesis. 
The AA genotypes in this study were higher in patients and reaching 
a significant level may cause low level of IL-10 in the serum of the pa-
tients with RRMS. The Rieckmann et al. (1995) showed that IL-10 is up- 
regulated in stable than active RRMS but Van Boxel-Dezaire et al. (1999) 
found that it down-regulated in patients during attacks, one of the 
causes of decreasing IL-10 in MS is due to polymorphism of − 1082 G/A 
SNPs and G allele changed in IL-10 promoter region to A allele (Yılmaz 
et al., 2005). If IL-10 decreases due to − 1082 G/A SNPs, the Th will shift 
to Th1, cell-mediated immunity will predominate, inflammation will 
rise, the MHC-II will be up-regulated, the myelin basic protein (MBP) 
antigen will be presented by macrophage to Th lymphocyte and conse-
quently, the auto-immune disease is flared up (Abbas et al., 2019). When 
the IL-10 decreases, the epitope spreading, the appearance of cryptic 
antigen and bystander activation of the immune cell will happen which 
cause further aggravates of the disease (Abbas et al., 2019). 
The EDSS scores the severity of the disease; logistic regression un-
covered signification association with AA genotypes; similarly, ANOVA 
tests confirmed that there was signification difference between A allele 
carrying genotypes and non A allele carrying genotypes. Furthermore, 
logistic regression showed non signification association between AA 
genotypes and other genotypes (GA and GG). 
To be concluded, both the genotype and haplotypes, besides the 
allele frequency of IL-10 promoter gene − 1082 G/A SNP is a significant 
risk factor predisposing in developing MS disease susceptibility in our 
population. Additionally, EDSS scores are higher in carrier A alleles (GA 
and AA genotypes), which means that this polymorphism may increase 
the severity and susceptibility of the disease. Due to the small size of the 
sample, polymorphism of IL-10 without serum IL-10 determination, and 
homogenous ethicality of the population (Since all MS patients are 
Kurds), this study cannot explain the critical role and association of IL- 
10 promoter gene − 1082 G/A SNP in the pathogenesis of the MS. 
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